In accordance with applicable privacy legislation, the company Kedrion S.p.a., controller of the data acquired via this website, hereby informs the user that said website does not use profiling cookies to send advertising messages tuned to preferences expressed when browsing the internet. This website installs third party cookies. Continuing to browse, including by scrolling down and clicking on website elements, equates to consent.
For more information, also as regards the technical cookies used by the website and to refuse consent to the installation of individual cookies, please refer to the complete cookies disclosure.
You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
-
PLASMA & BIOTHERAPIES - 22-03-2017
Article by Prof. Farrugia and Daniela Scaramuccia published on “Biologicals”
International medical journal hosts review of contract plasma fractionation dynamics
read more -
PLASMA & BIOTHERAPIES - 08-11-2016
FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin
Announcement by Kedrion Biopharma and Kamada. Regulatory decision expected in August 2017
read more -
PLASMA & BIOTHERAPIES - 16-09-2016
Humanitarian Factor IX donation to Afghanistan
Kedrion Biopharma confirms its commitment to broaden access to therapies in developing Countries
read more -
PLASMA & BIOTHERAPIES - 13-09-2016
Kedrion and Kamada seek FDA approval of IgG as a post-exposure treatment
BLA has been submitted on September 1, 2016. Companies planning for decision from FDA in mid-2017
read more
Pages
For more information please contact: pressoffice@kedrion.com
Where 